持续性哮喘和慢性阻塞性肺疾病的新型及现有药物治疗选择

New and existing pharmacotherapeutic options for persistent asthma and COPD.

作者信息

Diamant Z, Tarasevych S, Clarke G W

机构信息

Department of Respiratory Medicine & Allergology, Institute for Clinical Science, Skane University Hospital, Lund, Sweden.

出版信息

Neth J Med. 2011 Nov-Dec;69(11):486-99.

DOI:
Abstract

Asthma and COPD are chronic inflammatory airway disorders with systemic manifestations. The two diseases have different airway inflammation, features of airway remodelling with subsequent pathophysiology and clinical presentation. The international management guidelines recommend stepwise pharmacotherapy depending on disease control and÷or disease stage, comprising relievers and overall uniform controller treatment, despite the heterogeneity across the conditions and treatment response. Despite effective medications per se, still too many patients remain uncontrolled and no treatment can definitely cure either of the conditions. This overview includes currently recommended pharmacotherapeutic options with novel and future treatment targets.

摘要

哮喘和慢性阻塞性肺疾病(COPD)是伴有全身表现的慢性炎症性气道疾病。这两种疾病具有不同的气道炎症、气道重塑特征以及随后的病理生理学和临床表现。尽管病情和治疗反应存在异质性,但国际管理指南建议根据疾病控制情况和/或疾病阶段进行逐步药物治疗,包括缓解药物和总体统一的控制治疗。尽管药物本身有效,但仍有太多患者病情未得到控制,而且没有任何治疗方法能绝对治愈这两种疾病。本综述包括目前推荐的药物治疗选择以及新的和未来的治疗靶点。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索